Unbalanced translocations involving chromosome arm 17p, where the TP53 tumor suppressor gene localizes, are rarely described in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), but recent use of molecular cytogenetic techniques have indicated a significant incidence of TP53 deletions, suggesting the involvement of chromosome 17p in these disorders. By conventional karyotype, we have identified unbalanced translocations involving 17p in 14 out of 123 (11%) CLL/SLL patients with clonal abnormalities. Cases were characterized by resistance to chemotherapy and a poor clinical outcome. The karyotypes presented a high incidence of complex rearrangements and 17p translocations were characterized by various partners. In 10 cases a centric fusion was assessed by fluorescent in situ hybridization (FISH) experiments using specific centromeric probes. The incidence of dicentric translocations in these series is therefore significantly higher than usually described, arising in up to 71% (10 out of 14 cases). In all cases, translocations led to a monosomy 17p and to a TP53 monoallelic deletion. The adverse clinical outcome confirms that structural abnormalities involving chromosome 17p are associated with disease progression in patients with chronic lymphoproliferative disorders.
Introduction
In B cell chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), clonal chromosome abnormalities are identified in approximately 50% of patients. 1 However, conventional karyotype analysis has been often hampered by the low in vitro mitotic activity of the tumoral cells. 2 Recent improvement in fluorescence in situ hybridization (FISH) techniques has provided an alternative approach to assess the detection and the true incidence of chromosomal aberrations in those hematological malignancies. 3, 4 Among them, trisomy 12 and structural abnormalities of chromosome bands 13q14, 14q32 and 11q22-23 are the most common aberrations reported and may be associated with adverse clinical features. [5] [6] [7] In addition, in SLL (including leukemic forms), a del(6)(q21q23) has also been documented as a frequent recurrent chromosome abnormality. 8 In most conventional banding analysis of CLL/SLL, aberrations involving chromosome 17 have not been identified as frequent abnormalities. In the Second International Working Party on Chromosomes in CLL (IWCCLL), which compiled the cytogenetic data from 662 patients, 22 of 649 (4%) evaluable tumors had rearrangements of chromosome 17, mostly translocations of 17p, where the TP53 tumor suppressor gene localizes. 9 Further information about involvement of 17p came from a FISH study demonstrating TP53 deletions in 11 out of 90 (12%) patients with B-CLL. 10 More recently, using FISH analysis, we studied three CLL/SLL cases with a recurrent t(4;17) translocation and found that the rearrangement had retained the centromeres of both chromosomes, leading to the formation of a dicentric rearrangement and to the TP53 monoallelic deletion. 11 Those structural abnormalities of chromosome 17 with loss of material from the short arm through dicentric translocations have been rarely described in chronic lymphoproliferative disorders.
In the present study, we focused our interest on 17p translocations in patients with CLL/SLL. We identified 11 additional cases with rearrangements involving chromosome 17p and various other partners. To further characterize the chromosomal abnormalities, we investigated the cases by means of FISH using painting probes, centromeric probes and a specific TP53 DNA probe. We also analyzed the outcome of patients with tumoral cells carrying the 17p abnormalities.
Materials and methods

Patients
From February 1993 to October 1997, 226 patients with CLL/SLL were referred to our institution. Among them, 123 presented clonal chromosome abnormalities. In 14 cases, karyotypes displayed translocations involving the short arm of chromosome 17. Clinical and biological data of three patients have been previously reported. 11 All cases were reviewed by cyto-histopathologist experts. In 11 patients (eight males and three females) the diagnosis of B-CLL was assessed by the presence of a persistent lymphocytosis greater than 5 × 10 9 /l. In three cases, the diagnosis of SLL was based on clinical and cyto-histological findings: patients presented at diagnosis with disseminated lymph node enlargement, hepatomegaly and splenomegaly while the peripheral white blood counts were normal. In all cases, the tumoral cells displayed co-expression of the CD5, CD19 and CD23 antigens, an immunophenotype in agreement with the diagnosis of CLL/SLL. All medical records were reviewed for treatments and outcome, and response was assessed using the revised NCI criteria. 12 
Chromosome studies
Conventional cytogenetic studies were performed on peripheral blood, bone marrow or lymph nodes samples. Chromosome analyses were carried out on RHG-banded metaphases as previously described and evaluated according to the ISCN (1995) recommendations.
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Metaphase and interphase FISH Dual-color chromosome painting:
For FISH study, airdried slides with conventional chromosome preparations were used. Hybridization experiments were performed as previously reported with minor modifications. 11 The probes used were a biotin-labeled chromosome 17 probe (Oncor, Gaithersburg, MD, USA) and various digoxigenin-labeled paints specific for chromosomes 2, 4, 12, 13, 15, 18, 19, 20 and 22 (Oncor) . The probes cohybridized to metaphases at 37°C overnight, and slides were washed in 0.5 × SSC at 72°C for 5 min, followed by 1 × phosphate-buffered detergent (PBD; Oncor) for 2 min at room temperature. Hybridization signals were detected by the use of a layer of fluorescein isothiocyanate (FITC)-conjugated avidin antibodies (5 g/ml; Vector Laboratories, Burlingame, CA, USA) in combination with rhodamine-labeled antidigoxigenin antibodies (2 g/ml; Boehringer Mannheim, Germany). Slides were then counterstained with DAPI (0.1 g/ml) in an antifade solution, observed and photographed on a Zeiss epifluorescence axioskop equipped with the appropriate filter combinations using a Kodak ektachrome 400 film.
In a few cases, a second stage hybridization using additional paints was required. This prompted us to investigate the same slide repeatedly by applying various combinations of biotin-or digoxigenin-labeled probes. Consecutive experiments were then performed as described above. Signals related to probes applied in previous hybridizations were not visible using adequate labeled probes and detection systems or fluorochromes, as recently reported. 14 
FISH with ␣ satellite DNA probes:
Dual-color hybridization assays using appropriate centromeric-specific probes were performed as previously described, with minor modifications. 11 Briefly, 3 ng of both biotin and digoxigenin ␣-satellite DNA probes specific for respectively chromosome 17 and chromosomes 2, 4, 12, 13, 15, 18, 19, 20 and 22 (Oncor) , mixed with hybridization buffer were placed onto slides, covered with a 24 × 32 mm coverslip, simultaneously denaturated at 72°C for 2 min and placed for 1 h in a moist chamber at 37°C. After post-hybridization washes in 0.3 × SSC at 72°C for 5 min and in 1 × PBD at room temperature for 2 min, revelation of the signals was performed as described above.
FISH with TP53 cosmid DNA probe:
For single-color experiments, the technique was performed according to the manufacturer's recommendations (Oncor), except that the first post-hybridization wash was performed in 50% formamide/1 × SSC, pH 7 at 72°C. The TP53 cosmid probe displayed a single spot at the location of each copy of the TP53 gene. Thus, the expected number of chromosome 17 spots in a normal metaphase is four, one on each chromatid, while two are observed in a normal interphase nucleus.
Results
Chromosomal analysis
The analysis of R-banded chromosomes from lymphoid cells disclosed a near diploid karyotype with 44 to 47 chromosomes in 13 patients whereas in one patient (case 1) all the abnormal metaphases were in a tetraploid range (Table 1) . Complex karyotypes with multiple abnormal clones were observed in 11 of the 14 patients. Cells with a normal karyotype were identified in all cases except three (patients 2, 7 and 12). Partial karyotypes illustrating structural rearrangements involving chromosome 17 are shown in Figures 1  and 2 .
By conventional cytogenetic analysis, seven patients presented a derivative chromosome 17 resulting from a translocation involving 17p11 and 2q11 (patient 1), 13q11 (patient 2), 15q15 (patient 3), 18q11 (patients 4-6), and either 15q11, 20q11 or 22q11 in patient 7 for whom a jumping translocation was identified. Moreover, in patient 3 the derivative chromosome was observed in two related clones, leading to a der(17)t (15;17) in the stemline clone and to a der(17)t(4;17)t (15;17) in an additional deviating subclone.
In the remaining seven patients the consistent cytogenetic abnormality resulted in loss of a chromosome 17 and the presence of unbalanced rearrangements involving chromosome 17, in a segment distal to 17q11 and either chromosome 12p (patients 8 and 9), 12q (patient 10), 19q (patient 11) or 4p (patients [12] [13] [14] . In patients 8 and 9, the derivative chromosomes 12 were interpreted as der (12)t(12;17)(p12;q11). In patient 10, the derivative chromosome 12 was generated by two translocations, one involving the short arm, resulting from a translocation between band 12p13 and the segment 18q24 → 18 qter and the other involving the long arm, with a translocation of the segment 17q11→17 qter to band 12q15. In patient 11, the same chromosome 17 was involved in two distinct clones leading to a der(19) t(17;19)(q11;q13) in the stemline clone and to a der(2) t(2;17)(p24;q11) in an additional unrelated clone.
Associated clonal abnormalities were identified in all patients, except one (patient 4) who presented the der(17)t(17;18) as the sole cytogenetic abnormality. Other aberrations that have been described previously in low-grade non-Hodgkin's lymphomas were noted in several patients, namely a 13q deletion in three cases (patients 6, 7 and 8), a trisomy 12 in three cases (patients 2, 9 and 13) and a 6q deletion in three other cases (patients 6, 10 and 12).
In situ hybridization studies Dual-color chromosome painting:
In 10 cases (patients 1-5, 7, 10, 12-14), dual-color chromosome painting experiments confirmed the interpretations of the conventional analysis, whereas in four cases (patients 6, 8, 9 and 11), painting studies demonstrated more complex rearrangements leading to perform consecutive experiments using other paints. In patient 6, in addition to the unbalanced 17p rearrangement, painting analysis demonstrated the presence of chromosome 17 material on a seemingly acrocentric chromosome ( Figure  2 , top). A consecutive experiment with a chromosome 15 paint, corresponding to the chromosome which, because of similarities in the banding pattern, was considered to be the best candidate for having extra unidentified material, confirmed the presence of a der(15)t(15;17)(q14; p or q). In patient 8, an additional fluorescent 17 signal located on the tips of a large metacentric chromosome was also identified (Figure 2 , center). A second-stage hybridization using a chromosome 2 paint confirmed the presence of an unbalanced translocation t(2;17)(q37; p or q). In patient 9, in addition to a der (12) bottom). According to the FISH international nomenclature the additional marker was redesigned as a mar.isht(12;17) (wcp12+,wcp17+). In patient 11, in addition to the derivative chromosome 19, hybridization experiments also demonstrated the presence of chromosome 17-DNA sequences located on a small marker chromosome that we interpreted as an extra mar.ish der(17)(wcp17+).
FISH with ␣ satellite DNA probes:
To determine the centromeric origin on the rearranged chromosomes, metaphase FISH experiments using specific centromeric probes were further performed. In all abnormal cells, the consistent molecular finding was the presence of both chromosome 17 centromeres. In three patients (cases 1-3), the rearranged chromosomes contained only chromosome 17-specific alphoid DNA sequences, confirming the banding interpretations of der (17) . In contrast, in nine patients (cases 4-7, 8, 10 and 12-14), FISH analysis indicated that the derivative chromosome had retained centromeric repetitive sequences of both chromosomes involved in the translocation, leading to dicentric chromosomes. In the two remaining cases (patients 9 and 11), FISH analysis indicated that the rearranged chromosomes had retained only centromeres of the partner chromosomes, leading to derivative chromosomes 12 and 19 respectively, whereas 17-specific centromeric sequences were located on the marker chromosomes. Based on the banding and FISH results, the marker chromosomes were redesigned der(17)del(17)(p11)t(12;17)(p or q; p11) in patient 9 and der(17)(:p11→q11:) in patient 11. Furthermore, in the latter patient, who presented an unrelated clone with a der(2)t(2;17), FISH data indicated the presence of centromeres of both partners on the derivative chromosome, leading to a dic(2;17)(p24;p11).
FISH with TP53 cosmid DNA probe:
To analyze the possible involvement of the 17p13.1 region in which TP53 is located, single-color FISH experiments were further realized using a TP53 probe. In 13 patients (cases 2-14), the study was performed on metaphase and interphase cells whereas, in patient 1, because of the coexistence of diploid and tetraploid nuclei, both thought to display two 17p signals, only tetraploid metaphases were analyzed. Normal controls were included to determine the cut-off level for the diagnosis of a TP53 deletion. Two hundred interphase nuclei were scored for both patient and control samples. In all cases, the percentage of nuclei with one TP53 signal ranged from 7.5% to 83.5%, compared with only 4% in normal controls (Table 2) . Further FISH analysis on metaphase cells localized the signal on the remaining normal chromosome 17. In patient 1 we also identified a monoallelic TP53 deletion on all the tetraploid metaphases. Furthermore, in one case (patient 6), nullisomy for the TP53 probe was observed in less than 10% of interphase nuclei. This was corroborated by metaphase FISH in three out of 15 mitoses. Based on the banding analysis, the nullisomic population was related to the metaphases characterized by the coexistence of a monosomy 17 and a dic(17;18), both abnormalities leading to the loss of chromosome 17 short arms.
Cyto-histological features
In 13 out of 14 cases, slides of peripheral blood, bone marrow and/or lymph nodes made at the same time as the cytogenetic analysis could be reviewed. All cases had varying proportions of cells with features characteristic of CLL, with clumped chromatin, no visible nucleoli, and a small amount of cytoplasm. Two cases were classified as atypical CLL with more than 15% cleaved nuclei or plasmacytoid cells, and nine other cases had more than 10% prolymphocytes (PL). These nine cases were classified as CLL/PL, LL/PL or mixed-cell of polymorphous subtype, according to the French-American-British cooperative group (FAB) classification. 15 Five cases were studied at the time of diagnosis and all of them displayed a significant prolymphocytic component.
Clinical characteristics and outcome
This heterogeneous series includes patients whose karyotype was performed at diagnosis or at variable time points during Table 2 TP53 interphase fluorescence in situ hybridization results
Patients
No. of signals per nucleus (%) disease course and treatments. Overall, the median time from diagnosis to cytogenetic analysis was 40 months, ranging from 0 to 140 months (Table 3 ). The median age was 64 years, and treatments were adapted to the clinical and biological features of the disease and included chlorambucil, anthracyclin containing polychemotherapy or fludarabine. One patient received no treatment because of her age (81 years) and poor underlying medical conditions. However, when considering the response to the last treatment performed (or the first treatment for patients at diagnosis), nine out of the 13 (69%) patients treated were unresponsive (stable disease) or had experienced disease progression. Only one and three patients had a partial or a minor response, respectively. Overall, 10 out of the 14 (71%) patients died at a median of 50 months after diagnosis, the median follow-up of patients remaining alive being 22 months. Of note, from the time of cytogenetic examination showing the 17p abnormality, 10 patients have died and four are alive, the median survival time being 16 months.
Discussion
The cytogenetic analysis of 123 patients with CLL/SLL and clonal abnormalities identified 14 patients (11%) with aberrations involving the short arm of chromosome 17. These results are in accordance with a recent report in which chromosome 17p rearrangements were documented in 12% of patients with B-CLL. 10 The occurrence of this abnormality together with a trisomy 12 (patients 2, 9 and 13), a 13q deletion (patients 6, 7 and 8) and a 6q deletion (patients 6, 10 and 12) is in accordance with the non-random occurrence of 17p anomalies as a secondary change in CLL/SLL. However, one case (patient 4) had a t(17;18) as a sole abnormality indicating that this rearrangement can be isolated. Using FISH experiments we identified two distinct rearrangements, both resulting in 17p loss. One of these was a translocation resulting from centric fusion, while the other involved pericentromeric chromosome 17 breakpoints, 17p11 or 17q11. Furthermore, in two cases, both dicentric and non-dicentric abnormalities were identified, either in the same clone (patient 8) or in two unrelated clones (patient 11). The incidence of dicentric rearrangements in our series of 17p translocations arises in up to 71% (10 out 14 cases).
Such a high incidence of chromosome 17-dicentric rearrangements in lymphoproliferative disorders has not been reported so far. Although rarely observed in lymphoproliferative disorders, the 17p translocations previously reported are rather non-dicentric than dicentric rearrangements. 10, [16] [17] [18] We only found five descriptions of dicentric anomalies, namely four cases of dic (17;18) and one case of dic (8;17) , all of them being assessed using FISH analysis. 10 In addition to these cases, the present study describes three new whole-arm translocations dic (17;18) . Therefore, it appears that dic(17;18) may represent the most frequent recurrent dicentric abnormality in these disorders. Our study also shows that chromosome 17p can translocate, through dicentric abnormalities, onto many other chromosomes, giving altogether more than nine translocation partners (chromosomes 2, 4, 12, 13, 15, 18, 19, 20, 22) . Strikingly, in the cases of non-dicentric 17p translocations reported by others using conventional cytogenetic techniques, breakpoints invariably occurred within the pericentromeric regions of both partner chromosomes. However, the cytogenetic descriptions of most of these cases have not been completed by FISH investigations. As our study indicates, regular banding analysis cannot discriminate between genuinely centromeric breaks and breaks occurring within the euchromatin close to the centromeres. Therefore, it would be interesting to analyze the previous reported translocations with a reliable method such as FISH to precisely define if the centromeres of both partners are involved.
Renewed interest in human dicentric chromosomes stems from the finding that acquired dicentric rearrangements can be found in human leukemias and tumors. 19, 20 In hematological malignancies, including lymphoid and myeloid disorders, rare dicentric anomalies have been described: dic(7;12), dic(9;12) and dic (9;20) in acute lymphocytic leukemia (ALL); dic(12;17) and dic(17;18) in de novo or therapy-related acute myeloid leukemia and myelodysplastic syndrome. 18, [21] [22] [23] [24] [25] Of interest, in childhood B-ALL, dic(9;12) is associated with a fav-467 orable prognosis, regardless of other clinical features or specific therapy. 22 The physical structure of centromeres are variable from one chromosome to the other and prone to extreme polymorphism. Moreover, one still does not know if they contain any coding genes. 20 Outside of their principle role in the chromosome segregation during cell division, no other function has been assigned to these regions. The occurrence of dicentric translocations involving chromosome 17 and various partners suggests that a potential recurrent breakpoint in this chromosomal segment could be associated with human tumors. A more accurate study of the centromeric regions may lead to a better understanding of the putative mechanisms involved in these rearrangements.
One of the genetic consequences of the chromosome 17p unbalanced translocations, either dicentric or not dicentric, is the loss of a copy of the TP53 tumor suppressor gene which is located to the 17p13.1 region. Evidence for a role of TP53 in hematological malignancies including myeloid and lymphoid disorders came from molecular studies demonstrating TP53 mutations in these diseases. 25, 26 In CLL/SLL, the significant involvement of 17p and its contribution to tumor progression and resistance to therapy have been reported by others. 10, 17, 27 Although this retrospective study precludes definitive conclusion, most patients with 17p abnormality seemed to be refractory to chemotherapy, as reflected by their morphological features, their poor response to treatment and a short survival duration after the detection of this abnormality.
The common cytologic feature of the majority of our cases (nine out of 14 patients) consisted of the presence of a significant component of prolymphocytic cells. Trisomy 12 and del(6q) have been previously associated with atypical morphology in CLL, either CLL/PL (prolymphocytic leukemia) or CLL with cleaved nuclei. 28 A link between TP53 mutations and CLL/PL has also been recently reported. 29 Therefore, it is more likely that increase in prolymphocytic component constitutes a feature of aggressive disease regardless of the chromosome abnormality (trisomy 12, del(6q) or del(17p)). In our series, since sequential cytologic and cytogenetic samples were not available for all cases, it was not possible to determine whether the cytologic changes were associated or not with the occurrence of chromosome 17 rearrangements.
Despite the heterogeneity in disease history and treatments, these observations contrast with the usual clinical course of CLL/SLL patients. This is particularly true for the five patients in whom the cytogenetic analysis was performed within the first 6 months of diagnosis, since four of them appeared refractory to their first line of treatment. In the present study, chemotherapy refractoriness appears to involve various chemotherapeutic agents, including alkylating agents, anthracyclin and purine analogs. Whether or not the dicentric translocation is of any prognostic significance within the whole group of patients with 17p rearrangements cannot be assessed in this study, given the limited number of patients carrying nondicentric translocations. In addition, mutations of TP53, that affect the p53 protein expression or function, on the remaining allele have been usually found to be present in cells carrying a 17p monoallelic deletion, leading to the loss of p53 activity in these cells. Although these mutations were not documented in the present observations, one patient (case 6) demonstrated a TP53 biallelic deletion. 10 Of note, this 43-year-old patient died 3 months after diagnosis.
Altogether, these results confirm that structural abnormalities of chromosome 17p and TP53 monoallelic deletions seem to be associated with disease progression in patients with chronic lymphoproliferative disorders. Furthermore, our data suggest that centromeric fusion involving chromosome 17 is not uncommon in CLL/SLL and represents an additional and recurrent mechanism leading to TP53 monoallelic deletions.
